Sinovac Biotech Ltd
SVQ
Company Profile
Business description
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its products include vaccines for hepatitis A, hepatitis B, EV-A71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella, mumps, and tetanus. The Company generates maximum revenue from Mainland China.
Contact
No.39, Shangdi Xi Road
Haidan District
Beijing100085
CHNT: +86 1082799800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,643
Stocks News & Analysis
stocks
ASX property share lifts guidance despite sector headwinds
Aussie property manager lifts earnings expectations despite interest rate uncertainty.
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,904.70 | 26.20 | 0.30% |
| CAC 40 | 8,173.11 | 85.15 | -1.03% |
| DAX 40 | 25,184.89 | 204.21 | -0.80% |
| Dow JONES (US) | 50,461.68 | 118.02 | -0.23% |
| FTSE 100 | 10,491.39 | 25.13 | 0.24% |
| HKSE | 25,381.51 | 217.94 | -0.85% |
| NASDAQ | 26,656.18 | 312.21 | 1.19% |
| Nikkei 225 | 65,633.61 | 637.52 | 0.98% |
| NZX 50 Index | 13,207.71 | 137.97 | 1.06% |
| S&P 500 | 7,519.12 | 45.65 | 0.61% |
| S&P/ASX 200 | 8,674.80 | 22.60 | 0.26% |
| SSE Composite Index | 4,099.23 | 46.14 | -1.11% |